New insights into HL biology
Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.
Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.
Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.
Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.
By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.
By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.
The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.
Scientists in Germany have successfully reprogrammed liver cells, turning them into pancreas progenitor cells by altering a single gene. The team behind the breakthrough, at the Max Delbrück… read more.
Scientists in Germany have successfully reprogrammed liver cells, turning them into pancreas progenitor cells by altering a single gene. The team behind the breakthrough, at the Max Delbrück… read more.
Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.
Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.
Maintenance therapy with lenalidomide can improve PFS in patients with newly-diagnosed MM by almost two years compared with observation alone, in patients of all ages and all risk… read more.
High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.